Evidence map›Paper›PMID 28253732›Full record

ArticleAntioxidants & redox signaling2017

The Indirubin Derivative 6-Bromoindirubin-3'-Oxime Activates Proteostatic Modules, Reprograms Cellular Bioenergetic Pathways, and Exerts Antiaging Effects.

Eleni N Tsakiri, Nicolas Gaboriaud-Kolar, Kalliopi K Iliaki, Job Tchoumtchoua, Eleni-Dimitra Papanagnou, Sofia Chatzigeorgiou, Konstantinos D Tallas, Emmanuel Mikros, Maria Halabalaki, Alexios-Leandros Skaltsounis and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Antioxidants & redox signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Eleni N Tsakiri1 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens , Athens, Greece .
Nicolas Gaboriaud-Kolar2 Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens , Athens, Greece .
Kalliopi K Iliaki1 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens , Athens, Greece .
Job Tchoumtchoua2 Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens , Athens, Greece .
Eleni-Dimitra Papanagnou1 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens , Athens, Greece .
Sofia Chatzigeorgiou1 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens , Athens, Greece .
Konstantinos D Tallas1 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens , Athens, Greece .
Emmanuel Mikros3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens , Athens, Greece .
Maria Halabalaki2 Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens , Athens, Greece .
Alexios-Leandros Skaltsounis2 Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens , Athens, Greece .
Ioannis P Trougakos1 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens , Athens, Greece .
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsOrganismal aging can be delayed by mutations that either activate stress responses or reduce the nutrient-sensing pathway signaling; thus, by using Drosophila melanogaster as an in vivo experimental screening platform, we searched for compounds that modulate these pathways.

resultsWe noted that oral administration of the glycogen synthase kinase 3 (Gsk-3) inhibitor 6-bromoindirubin-3'-oxime (6BIO) in Drosophila flies extended healthy life span. 6BIO is not metabolized in fly tissues, modulated bioenergetic pathways, decreased lipid and glucose tissue load, activated antioxidant and proteostatic modules, and enhanced resistance to stressors. Mechanistically, we found that the effects on the stress-responsive pathways were largely dependent on the activity of the transcription factor nuclear factor erythroid 2-related factor (Nrf-2). Genetic inhibition of Gsk-3 largely phenocopied the 6BIO-mediated effects, while high levels of Gsk-3 expression and/or kinase activity suppressed proteostatic modules and reduced flies' longevity; these effects were partially rescued by 6BIO. Also, 6BIO was found to partially reduce the 3-phosphoinositide-dependent protein kinase-1 (Pdpk1) activity, a major effector of the insulin/insulin-like growth factor-1 cell signaling pathways. INNOVATION: 6BIO exerts the unique property of increasing stress tolerance and in parallel partially suppressing the nutrient-sensing pathway signaling.

conclusionOur findings suggest that the 6BIO scaffold can be used for the development of novel antiaging compounds. Antioxid. Redox Signal. 27, 1027-1047.

Indexed as

Administration, OralAgingAnimalsDisease Models, AnimalDrosophila melanogasterDrosophila ProteinsEnergy MetabolismFemaleGlycogen Synthase Kinase 3HumansIndolesMaleMetabolic Networks and PathwaysNF-E2-Related Factor 2OximesProteostasis6-bromoindirubin-3'-oximeDrosophila ProteinsGlycogen Synthase Kinase 3IndolesNF-E2-Related Factor 2Oximes6-bromoindirubin-3′-oximeagingGsk-3Nrf-2Pdpk1proteostasis

Identifiers

PMID28253732
PMCPMC5651956
OpenAlexW2594610415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.